Podcast Index
Explora podcasts por categoría, abre episodios recientes y descarga audio para escucharlo sin conexión.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus
BZ Group
Delving In with Stuart Kelter
Stuart Kelter
The Deep-Sea Podcast
Thomas Linley
TED-Ed
TED-Ed
God's Eye View
Trevor
The Poison Lab
Clinical Toxicology LLC
絮言．狂想 seoijin
以色列、三苗、靳尼
Tommy Cullum's Let's Get Freaky
Tommy Cullum
The Relational Social Work Podcast
Matt and Hannah
GU Cast | Urology Podcast
Professor Declan Murphy & Dr Renu Eapen
Designing Healthcare that Cares Podcast
Doctor Podcast Network, Dr. Laura Suttin
Thrilling Threads - Conspiracy Theories, Strange Phenomena, True Crime, Unsolved Mysteries, etc!
Byte & Pieces
PBS Space Time
PBS
Almanacco del giorno
Streammo
Slick Slime Sam
TheSoul Publishing
Hillbilly Horror Stories Paranormal Podcast
Jerry Paulley
ReddX Reddit Reads
ReddX
Arroe Collins Forest Stories
Arroe Collins
The GMP Insider
Tushar Arora
Two Money Lovers 經濟學不是萬能但有用
季凡 & 翔蛇
Matt From Nomad’s
Matt Crabtree
The Political Cesspool Radio Show Podcast Feed
James Edwards
Next-gen Hills Naturalists
Coen and Eve
The Christian Mind Reset
The Christian Mind Reset
Maintenant Vous Savez Santé
Bababam
Vedanta Cast
Jonas Masetti
Soif de Sens | Écologie & social
Pierre Chevelle | Écologie
London Weather Daily
Fast Foundations
Talking Rubbish - Recycled Content
James Piper, Robbie Staniforth
EXTRA ANORMAL
iEX Studios
The Medbullets Step 2 & 3 Podcast
Medbullets
Exploring Humanity Through Sci-Fi
Tony Tellado
De Universiteit van Nederland Podcast
Universiteit van Nederland
The Future Conceived
SSR Podcast
On This Day in Working Class History
Working Class History
Geladen - der Batteriepodcast zur Energiewende
Daniel Messling, Patrick von Rosen
JP Lovecraft's Creepy Podcast
JP Lovecraft
Ciencia
BZ Group
FDA breaks Amgen's Tepezza monopoly with Viridian's Lumvoa approval in thyroid eye disease. Plus Merck KGaA's $11.3B Bio-Techne acquisition, Biogen gutting the Apellis pipeline post-$5.6B deal, CHMP moves to revoke Tavne...
FDA approves Ionis Tryngolza as first treatment to reduce pancreatitis risk in severe hypertriglyceridemia — a potential blockbuster expansion. Merck KGaA acquires Bio-Techne for $11.3B in largest deal in a decade. SCOTU...
Gilead's Trodelvy wins front-line triple-negative breast cancer approval — and the stock barely moves. Lilly expands its Abbisko partnership to $1.9B, Novartis pays $105M upfront to Antares for undruggable cancer targets...
Pfizer's sigvotatug vedotin disappoints in Phase 3 NSCLC — another blow to the $43B Seagen deal. Plus CMS settles with Incyte on Opzelura classification, Sangamo Therapeutics closes after 30 years, and Moderna's flu vacc...
AbbVie bets $10.9B on Apogee Therapeutics to challenge Dupixent — its biggest deal since Allergan. Plus: the first CAR-T approved for a solid tumor clears in China, Merck's $10.8B Prometheus IBD bet pays off with a Phase...
US government opens formal probe into Germany's drug pricing reforms, escalating transatlantic pharma trade tensions. Kardigan IPO raises $400M and pops 31%. Moderna flu vaccine gets unanimous FDA advisory panel support ...
Moderna's mRNA flu vaccine gets unanimous FDA panel backing — PDUFA August 5. NovoCure's TRIDENT trial misses overall survival in glioblastoma; stock drops ~18%. Biogen acquires immunology startup RayThera for up to $1B;...
UniQure surges 70% as FDA reverses course on Huntington's gene therapy AMT-130 filing path. Jazz and AbCellera strike $4.1B T cell engager deal for GI cancers. Novo Nordisk faces $25M ransom demand after hackers claim dr...
BridgeBio's BBP-418 sweeps Phase 3 in limb-girdle muscular dystrophy — stock up 15%, no approved competition. FDA briefing docs challenge Moderna mFlusiva efficacy ahead of Thursday's VRBPAC vote. Plus Lilly acquires non...
CMS proposes closing Medicare negotiation loophole threatening Keytruda and Opdivo subcutaneous strategies — billions at stake. Plus Takeda's zasocitinib tops Sotyktu, Novartis validates $12B Avidity deal, Elicio's KRAS ...
The Pharma Closeout's comprehensive recap of EHA 2026(Stockholm, June 11-14). HEADLINE: J&J's MonumenTAL-3 (talquetamab +daratumumab) in earlier-line R/R myeloma — PFS HR 0.28/0.33, complete-response 71% vs 34.5%, NEJM-p...
FDA approves Merck's Welireg-Keytruda combo for adjuvant kidney cancer — 28% risk reduction vs. active Keytruda monotherapy in LITESPARK-022. Jazz's Zepzelca misses OS endpoint in Phase 3 LAGOON, Incyte acquires Vega The...
Zasocitinib hits 35% complete skin clearance at week 16,topping Sotyktu by more than 2.5x in Takeda's head-to-head Phase 3. Plus: Novartis validates its $12B Avidity AOC platform in FSHD, Summit withdraws $500M offering,...
Parabilis Medicines prices the largest-ever venture-backed biotech IPO at $670M as 12 startups top $4.1B in 2026. Sanofi stops MOBILIZE Phase 3 for riliprubart in CIDP. TG Therapeutics surges on Briumvi myasthenia gravis...
The Pharma Closeout's full recap of the American Diabetes Association's 86th Scientific Sessions (New Orleans,June 5-8, 2026) - the meeting that ended the A1C-only era and reset what obesity medicine can do. Hosts Alex M...
In about six weeks this spring, four of the biggest names in pharma each picked an AI partner — Bristol Myers Squibb chose Anthropic's Claude for 30,000+ employees, Merck signed with Google Cloud for up to $1B, Novo Nord...
Alnylam commits up to $2B to Inceptive Nucleics forAI-driven RNAi drug discovery — $30M upfront, milestone-heavy structure. Lundbeck's bocunebart hits Phase IIb primary endpoint with 1.38-day treatmentdifference in refra...
SCOTUS unanimously backs Hikma's skinny-label Vascepa generic, reshaping patent defense for branded pharma. ADC Therapeutics drops 50%+ on LOTIS-5 death rate (13.2% vs 4.6%), biotech M&A crosses $106B in 2026, and Legend...
Part 2 of The Pharma Closeout's ASCO 2026 special covers the closing days, MondayJune 1 and Tuesday June 2 — net-new readouts plus resolution of Part 1's June 1-2 watch-list. HEADLINE: izalontamab brengitecan (iza-bren),...
ASCO 2026 comprehensive opening-weekend recap (28 readouts through Sunday, May 31). Headline: Revolution Medicines' RASolute 302 doubles overall survival in second-line pancreatic cancer (daraxonrasib, 13.2 vs 6.7months,...
Completa el formulario de abajo. Asegúrate de seleccionar tanto País como Géneros.
Envíanos un mensaje abajo. Te responderemos en un plazo de 24 horas.